Project description:SNP array data from 45 adrenocortical carcinomas were used to detect recurrent copy number alterations. 7 tumors were analyzed with Illumina Human610-Quad v1.0 BeadChip. 38 tumors were analyzed with Illumina HumanOmniExpress BeadChip.
Project description:SNP array data from 127 hepatocellular adenomas and carcinomas were used to detect recurrent copy number alterations. 48 tumors were analyzed with Illumina HumanCNV370-Duo v1.0 chips. 79 tumors were analyzed with Illumina HumanOmniExpress BeadChip.
Project description:Genome wide DNA methylation profiling of phyllodes tumour, fibroadenoma and metaplastic breast cancer samples. The Illumina Infinium Methylation EPIC v1.0 BeadChip Array was used to obtain DNA methylation profiles across approximately 866,000 CpGs from primary tumours. Samples included a range of grades of phyllodes tumours (n=29), fibroadenoma (n=2), and metaplastic breast cancer (n=2).
Project description:SNP array data from 125 hepatocellular carcinomas were used to detect recurrent copy number alterations. 99 hepatocellular carcinomas and 86 matched normal samples were analyzed with Illumina HumanCNV370-Duo v1.0 chips. 26 hepatocellular carcinomas and 26 matched normal samples were analyzed with Illumina HumanOmniExpress BeadChip.
Project description:SNP array data from 12 childhood adrenocortical tumors (ACT) were used to identify recurrent chromosome rearrangements and candidate driver genes. 12 childhood ACT were analyzed with Illumina Human610-Quad v1.0 BeadChips.
Project description:Genome wide DNA methylation profiling of primary cultures of normal and diabetic corneolimbal epithelial cells. The Illumina Infinium MethylationEPIC Human DNA methylation Beadchip v1.0 B4 was used to obtain DNA methylation profiles across approximately 850,000 CpGs.
Project description:Background: In vitro models are an essential tool towards understanding the molecular characteristics of colorectal cancer (CRC) and the testing of therapies for CRC. To this end we established 21 novel CRC cell lines of which six were derived from liver metastases. Extensive genetic, genomic, transcriptomic and methylomic profiling was performed in order to characterize these new cell lines and all data is made publically available. Additionally, sensitivity of oxaliplatin was tested as a measure for chemotherapy resistance. Results: DNA copy-number alterations (CNA) were compared between primary and metastasis derived cell lines. In concordance with previous studies copy-number gain of chr20, and loss of chr8p were found highly specific for liver metastases. Previously reported BRAF-mutation associated DNA methylation profiles could be validated on the genome-wide DNA methylation profiles of these cell lines. 47.6% of the loci previously reported to associate with BRAF mutation status were reproduced in this dataset. When examining the gene expression profiles in conjunction with these DNA methylation results, we identified 20 genes of which the gene expression correlated with the DNA methylation status, including MEIS1, LRAT and STC2. These genes have previously been reported to be subject to transcriptional regulation through DNA hypermethylation, validating our approach. Conclusions: By combining mutation profiles with CNA and gene expression profiles we constructed an overview of the alterations in the major CRC-related signalling pathways. The mutation profiles, along with the genome, transcriptome and methylome data of these cell lines will be made publically available . This combined dataset puts these cell lines among the best characterized CRC cell lines, allowing researchers to select appropriate cell line models for their particular experiment, making optimal use of these novel cell lines as in vitro model for CRC. SNP-array analysis of 21 novel CRC cell lines; 16 with Illumina HumanExome-12 v1.2 BeadChip and 5 with Illumina HumanExome-12 v1.0 BeadChip.
Project description:Background: In vitro models are an essential tool towards understanding the molecular characteristics of colorectal cancer (CRC) and the testing of therapies for CRC. To this end we established 21 novel CRC cell lines of which six were derived from liver metastases. Extensive genetic, genomic, transcriptomic and methylomic profiling was performed in order to characterize these new cell lines and all data is made publically available. Additionally, sensitivity of oxaliplatin was tested as a measure for chemotherapy resistance. Results: By combining mutation profiles with CNA and gene expression profiles we constructed an overview of the alterations in the major CRC-related signalling pathways. The mutation profiles, along with the genome, transcriptome and methylome data of these cell lines will be made publically available . This combined dataset puts these cell lines among the best characterized CRC cell lines, allowing researchers to select appropriate cell line models for their particular experiment, making optimal use of these novel cell lines as in vitro model for CRC. Conclusions: By combining mutation profiles with CNA and gene expression profiles we constructed an overview of the alterations in the major CRC-related signalling pathways. The mutation profiles, along with the genome, transcriptome and methylome data of these cell lines will be made publically available . This combined dataset puts these cell lines among the best characterized CRC cell lines, allowing researchers to select appropriate cell line models for their particular experiment, making optimal use of these novel cell lines as in vitro model for CRC. SNP-array analysis of 21 novel CRC cell lines; 16 with Illumina HumanExome-12 v1.2 BeadChip and 5 with Illumina HumanExome-12 v1.0.